Role of Non-conventional T Lymphocytes in Respiratory Infections: The Case of the Pneumococcus

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Ivanov, Stoyan ^a,b,c   Paget, Christophe ^a,b,c   Trottein, François ^a,b,c  

^a INSERM U1019   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; GRANZYME; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR; PERFORIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VIRULENCE FACTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE RELEASE; CYTOLYSIS; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MUCOSAL ASSOCIATED INVARIANT T CELL; NATURAL KILLER T CELL; NONHUMAN; PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MUCOSA; RESPIRATORY TRACT INFECTIONS; T LYMPHOCYTE SUBPOPULATION;

STREPTOCOCCUS PNEUMONIAE;

ANIMALS; HUMANS; MUCOUS MEMBRANE; NATURAL KILLER T-CELLS; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; T-LYMPHOCYTE SUBSETS;

EID: 84908334089     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004300     Document Type: Review

References (162)

1. Bartlett JG, Breiman RF, Mandell LA, File TM, Jr (1998) Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 26: 811–838.
2. File TM, (2003) Community-acquired pneumonia. Lancet 362: 1991–2001.
3. Wroe PC, Finkelstein JA, Ray GT, Linder JA, Johnson KM, et al. (2012) Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 205: 1589–1592.
4. Welte T, Torres A, Nathwani D, (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67: 71–79.
5. Obaro S, Adegbola R, (2002) The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 51: 98–104.
6. Kadioglu A, Weiser JN, Paton JC, Andrew PW, (2008) The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6: 288–301.
7. van der Poll T, Opal SM, (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374: 1543–1556.
8. Vernatter J, Pirofski LA, (2013) Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 26: 277–283.
9. Mitchell AM, Mitchell TJ, (2010) Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect 16: 411–418.
10. McCullers JA, (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19: 571–582.
11. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ, (2010) Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care 14: 219.
12. Viasus D, Garcia-Vidal C, Carratala J, (2013) Advances in antibiotic therapy for community-acquired pneumonia. Curr Opin Pulm Med 19: 209–215.
13. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, et al. (2013) Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 31: 4881–4887.
14. Kyd JM, McGrath J, Krishnamurthy A, (2011) Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets 12: 521–530.
15. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27: 397–412.
16. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, et al. (2006) Pneumococcal vaccination in developing countries. Lancet 367: 1880–1882.
17. Rodgers GL, Klugman KP, (2011) The future of pneumococcal disease prevention. Vaccine 29 Suppl 3: C43–48.
18. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL, (2013) Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects. Vaccine 32: 133–145.
19. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R, (2004) Pneumococcal vaccines: an update on current strategies. Vaccine 22: 2209–2220.
20. Hausdorff WP, Bryant J, Paradiso PR, Siber GR, (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30: 100–121.
21. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, et al. (2003) Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422: 164–169.
22. Martin E, Treiner E, Duban L, Guerri L, Laude H, et al. (2009) Stepwise development of MAIT cells in mouse and human. PLoS Biol 7: e54.
23. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, et al. (2010) Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8: e1000407.
24. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, et al. (2011) Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117: 1250–1259.
25. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, et al. (1999) An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med 189: 1907–1921.
26. Porcelli S, Yockey CE, Brenner MB, Balk SP, (1993) Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 178: 1–16.
27. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, et al. (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491: 717–723.
28. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, et al. (2010) Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 11: 701–708.
29. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, et al. (2012) Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun 80: 3256–3267.
30. Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, et al. (2012) Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. Arthritis Rheum 64: 153–161.
31. Gold MC, Lewinsohn DM, (2013) Co-dependents: MR1-restricted MAIT cells and their antimicrobial function. Nat Rev Microbiol 11: 14–19.
32. Le Bourhis L, Mburu YK, Lantz O, (2013) MAIT cells, surveyors of a new class of antigen: development and functions. Curr Opin Immunol 25: 174–180.
33. Birkinshaw RW, Kjer-Nielsen L, Eckle SB, McCluskey J, Rossjohn J, (2014) MAITs, MR1 and vitamin B metabolites. Curr Opin Immunol 26: 7–13.
34. Gapin L, (2014) Check MAIT. J Immunol 192: 4475–4480.
35. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, et al. (2013) MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 9: e1003681.
36. Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, et al. (2013) Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. Mucosal Immunol 6: 35–44.
37. Meierovics A, Yankelevich WJ, Cowley SC, (2013) MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci U S A 110: E3119–3128.
38. Bonneville M, O'Brien RL, Born WK, (2010) Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10: 467–478.
39. Kalyan S, Kabelitz D, (2013) Defining the nature of human gammadelta T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol 10: 21–29.
40. Vantourout P, Hayday A, (2013) Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 13: 88–100.
41. Wands JM, Roark CL, Aydintug MK, Jin N, Hahn YS, et al. (2005) Distribution and leukocyte contacts of gammadelta T cells in the lung. J Leukoc Biol 78: 1086–1096.
42. Ferreira LM, (2013) Gammadelta T cells: innately adaptive immune cells? Int Rev Immunol 32: 223–248.
43. Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D, et al. (1994) Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci U S A 91: 8175–8179.
44. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, et al. (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155–158.
45. Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, et al. (2001) Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett 509: 317–322.
46. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, et al. (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163–168.
47. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, et al. (2000) Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 191: 937–948.
48. Russano AM, Bassotti G, Agea E, Bistoni O, Mazzocchi A, et al. (2007) CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol 178: 3620–3626.
49. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, et al. (2013) CD1d-lipid antigen recognition by the gammadelta TCR. Nat Immunol 14: 1137–1145.
50. Bukowski JF, Morita CT, Brenner MB, (1994) Recognition and destruction of virus-infected cells by human gamma delta CTL. J Immunol 153: 5133–5140.
51. Zeng X, Wei YL, Huang J, Newell EW, Yu H, et al. (2012) gammadelta T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response. Immunity 37: 524–534.
52. Zhang L, Jin N, Nakayama M, O'Brien RL, Eisenbarth GS, et al. (2010) Gamma delta T cell receptors confer autonomous responsiveness to the insulin-peptide B:9–23. J Autoimmun 34: 478–484.
53. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, et al. (2012) Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. Nat Immunol 13: 872–879.
54. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M, (2009) Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31: 321–330.
55. Conti L, Casetti R, Cardone M, Varano B, Martino A, et al. (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174: 252–260.
56. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, et al. (2006) Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol 176: 1386–1393.
57. Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E, (2009) Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol 183: 3625–3633.
58. Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ, (2012) Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity. J Immunol 188: 3928–3939.
59. Hayday AC, (2009) Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31: 184–196.
60. Zheng J, Liu Y, Lau YL, Tu W, (2013) gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol 10: 50–57.
61. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie JJ, Krensky AM, et al. (2001) Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 184: 1082–1085.
62. Qin G, Mao H, Zheng J, Sia SF, Liu Y, et al. (2009) Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis 200: 858–865.
63. Su D, Shen M, Li X, Sun L, (2013) Roles of gammadelta T cells in the pathogenesis of autoimmune diseases. Clin Dev Immunol 2013: 985753.
64. Dudal S, Turriere C, Bessoles S, Fontes P, Sanchez F, et al. (2006) Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against Brucella suis. J Immunol 177: 5533–5539.
65. Hamada S, Umemura M, Shiono T, Hara H, Kishihara K, et al. (2008) Importance of murine Vdelta1gammadelta T cells expressing interferon-gamma and interleukin-17A in innate protection against Listeria monocytogenes infection. Immunology 125: 170–177.
66. Tu W, Zheng J, Liu Y, Sia SF, Liu M, et al. (2011) The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J Exp Med 208: 1511–1522.
67. Li H, Xiang Z, Feng T, Li J, Liu Y, et al. (2013) Human Vgamma9Vdelta2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells. Cell Mol Immunol 10: 159–164.
68. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA, (2010) A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol 264: 71–77.
69. Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, et al. (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells. Eur J Immunol 38: 2200–2209.
70. Cheng P, Liu T, Zhou WY, Zhuang Y, Peng LS, et al. (2012) Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia. BMC Immunol 13: 38.
71. Janis EM, Kaufmann SH, Schwartz RH, Pardoll DM, (1989) Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 244: 713–716.
72. Peng MY, Wang ZH, Yao CY, Jiang LN, Jin QL, et al. (2008) Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 5: 203–208.
73. Lockhart E, Green AM, Flynn JL, (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177: 4662–4669.
74. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, et al. (2007) IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 178: 3786–3796.
75. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, et al. (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184: 4414–4422.
76. Saitoh T, Yano I, Kumazawa Y, Takimoto H, (2012) Pulmonary TCR gammadelta T cells induce the early inflammation of granuloma formation by a glycolipid trehalose 6,6′-dimycolate (TDM) isolated from Mycobacterium tuberculosis. Immunopharmacol Immunotoxicol 34: 815–823.
77. Scott-Browne JP, Matsuda JL, Mallevaey T, White J, Borg NA, et al. (2007) Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol 8: 1105–1113.
78. Bendelac A, Savage PB, Teyton L, (2007) The biology of NKT cells. Annu Rev Immunol 25: 297–336.
79. Berzins SP, Smyth MJ, Baxter AG, (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11: 131–142.
80. Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI, (2012) Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol 12: 845–857.
81. Brennan PJ, Brigl M, Brenner MB, (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13: 101–117.
82. Rhost S, Lofbom L, Rynmark BM, Pei B, Mansson JE, et al. (2012) Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur J Immunol 42: 2851–2860.
83. Berzofsky JA, Terabe M, (2009) The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 9: 667–672.
84. Scanlon ST, Thomas SY, Ferreira CM, Bai L, Krausz T, et al. (2011) Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J Exp Med 208: 2113–2124.
85. Cohen NR, Garg S, Brenner MB, (2009) Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity. Adv Immunol 102: 1–94.
86. Tupin E, Kinjo Y, Kronenberg M, (2007) The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5: 405–417.
87. Faveeuw C, Mallevaey T, Trottein F, (2008) Role of natural killer T lymphocytes during helminthic infection. Parasite 15: 384–388.
88. Tessmer MS, Fatima A, Paget C, Trottein F, Brossay L, (2009) NKT cell immune responses to viral infection. Expert Opin Ther Targets 13: 153–162.
89. Brigl M, Brenner MB, (2010) How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol 22: 79–86.
90. Paget C, Trottein F, (2013) Role of type 1 natural killer T cells in pulmonary immunity. Mucosal Immunol 6: 1054–1067.
91. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, 3rdet al. (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525–529.
92. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520–525.
93. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, et al. (2006) Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7: 978–986.
94. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. (2011) Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 12: 966–974.
95. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, et al. (2011) Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 208: 1163–1177.
96. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB, (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4: 1230–1237.
97. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, et al. (2007) Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27: 597–609.
98. Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, et al. (2007) Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci U S A 104: 20490–20495.
99. Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS, (2002) NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 76: 4294–4303.
100. De Santo C, Salio M, Masri SH, Lee LY, Dong T, et al. (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 118: 4036–4048.
101. Paget C, Ivanov S, Fontaine J, Blanc F, Pichavant M, et al. (2011) Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J Immunol 186: 5590–5602.
102. Paget C, Ivanov S, Fontaine J, Renneson J, Blanc F, et al. (2012) Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J Biol Chem 287: 8816–8829.
103. Kok WL, Denney L, Benam K, Cole S, Clelland C, et al. (2012) Pivotal Advance: Invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection. J Leukoc Biol 91: 357–368.
104. Bilenki L, Wang S, Yang J, Fan Y, Joyee AG, et al. (2005) NK T cell activation promotes Chlamydia trachomatis infection in vivo. J Immunol 175: 3197–3206.
105. Joyee AG, Qiu H, Wang S, Fan Y, Bilenki L, et al. (2007) Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J Immunol 178: 1048–1058.
106. Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB, (1999) Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 189: 1973–1980.
107. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM, (2008) Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 4: e1000239.
108. Skold M, Behar SM, (2003) Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 71: 5447–5455.
109. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, et al. (2000) Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci U S A 97: 4204–4208.
110. Szalay G, Zugel U, Ladel CH, Kaufmann SH, (1999) Participation of group 2 CD1 molecules in the control of murine tuberculosis. Microbes Infect 1: 1153–1157.
111. Chackerian A, Alt J, Perera V, Behar SM, (2002) Activation of NKT cells protects mice from tuberculosis. Infect Immun 70: 6302–6309.
112. Sada-Ovalle I, Skold M, Tian T, Besra GS, Behar SM, (2010) Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 182: 841–847.
113. Chiba A, Dascher CC, Besra GS, Brenner MB, (2008) Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol 181: 2292–2302.
114. Dieli F, Taniguchi M, Kronenberg M, Sidobre S, Ivanyi J, et al. (2003) An anti-inflammatory role for V alpha 14 NK T cells in Mycobacterium bovis bacillus Calmette-Guerin-infected mice. J Immunol 171: 1961–1968.
115. Im JS, Kang TJ, Lee SB, Kim CH, Lee SH, et al. (2008) Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin Immunol 127: 214–224.
116. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, et al. (2006) Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol 145: 252–260.
117. Paterson GK, Mitchell TJ, (2006) Innate immunity and the pneumococcus. Microbiology 152: 285–293.
118. Koppe U, Suttorp N, Opitz B, (2012) Recognition of Streptococcus pneumoniae by the innate immune system. Cell Microbiol 14: 460–466.
119. Hippenstiel S, Opitz B, Schmeck B, Suttorp N, (2006) Lung epithelium as a sentinel and effector system in pneumonia–molecular mechanisms of pathogen recognition and signal transduction. Respir Res 7: 97.
120. Zhang Z, Clarke TB, Weiser JN, (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119: 1899–1909.
121. Elhaik-Goldman S, Kafka D, Yossef R, Hadad U, Elkabets M, et al. (2011) The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS ONE 6: e23472.
122. Mitchell AJ, Yau B, McQuillan JA, Ball HJ, Too LK, et al. (2012) Inflammasome-dependent IFN-gamma drives pathogenesis in Streptococcus pneumoniae meningitis. J Immunol 189: 4970–4980.
123. Yamamoto N, Kawakami K, Kinjo Y, Miyagi K, Kinjo T, et al. (2004) Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma. Microbes Infect 6: 1241–1249.
124. Sun K, Salmon SL, Lotz SA, Metzger DW, (2007) Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun 75: 1196–1202.
125. Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, et al. (2007) Role of interferon-gamma in Valpha14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect 9: 364–374.
126. McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, et al. (2010) Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 6: e1001191.
127. Yamada M, Gomez JC, Chugh PE, Lowell CA, Dinauer MC, et al. (2011) Interferon-gamma production by neutrophils during bacterial pneumonia in mice. Am J Respir Crit Care Med 183: 1391–1401.
128. Weber SE, Tian H, Pirofski LA, (2011) CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol 186: 432–442.
129. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, et al. (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4: e1000159.
130. Ma J, Wang J, Wan J, Charboneau R, Chang Y, et al. (2010) Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 78: 830–837.
131. Li W, Moltedo B, Moran TM, (2012) Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 86: 12304–12312.
132. Cao J, Wang D, Xu F, Gong Y, Wang H, et al. (2014) Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol Med 6: 120–140.
133. Kadioglu A, Coward W, Colston MJ, Hewitt CR, Andrew PW, (2004) CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 72: 2689–2697.
134. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, et al. (2005) CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 102: 4848–4853.
135. Trzcinski K, Thompson CM, Srivastava A, Basset A, Malley R, et al. (2008) Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun 76: 2678–2684.
136. Wright AK, Bangert M, Gritzfeld JF, Ferreira DM, Jambo KC, et al. (2013) Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog 9: e1003274.
137. Van Maele L, Carnoy C, Cayet D, Ivanov S, Porte R, et al. (2014) Activation of Type 3 Innate Lymphoid Cells and Interleukin 22 Secretion in the Lungs During Streptococcus pneumoniae Infection. J Infect Dis 210: 493–503.
138. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, et al. (2013) Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol 13: 145–149.
139. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, et al. (2001) Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293: 498–506.
140. Lanie JA, Ng WL, Kazmierczak KM, Andrzejewski TM, Davidsen TM, et al. (2007) Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol 189: 38–51.
141. Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, et al. (2001) Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci U S A 98: 4658–4663.
142. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, et al. (2002) Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci U S A 99: 10078–10083.
143. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, et al. (2014) Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol 176: 266–274.
144. Nakasone C, Yamamoto N, Nakamatsu M, Kinjo T, Miyagi K, et al. (2007) Accumulation of gamma/delta T cells in the lungs and their roles in neutrophil-mediated host defense against pneumococcal infection. Microbes Infect 9: 251–258.
145. Kirby AC, Newton DJ, Carding SR, Kaye PM, (2007) Evidence for the involvement of lung-specific gammadelta T cell subsets in local responses to Streptococcus pneumoniae infection. Eur J Immunol 37: 3404–3413.
146. Kirby AC, Newton DJ, Carding SR, Kaye PM, (2007) Pulmonary dendritic cells and alveolar macrophages are regulated by gammadelta T cells during the resolution of S. pneumoniae-induced inflammation. J Pathol 212: 29–37.
147. Snelgrove RJ, Godlee A, Hussell T, (2011) Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol 32: 328–334.
148. Metzger DW, Sun K, (2013) Immune dysfunction and bacterial coinfections following influenza. J Immunol 191: 2047–2052.
149. Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, et al. (2003) Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 33: 3322–3330.
150. King IL, Amiel E, Tighe M, Mohrs K, Veerapen N, et al. (2013) The mechanism of splenic invariant NKT cell activation dictates localization in vivo. J Immunol 191: 572–582.
151. Ivanov S, Fontaine J, Paget C, Macho Fernandez E, Van Maele L, et al. (2012) Key role for respiratory CD103(+) dendritic cells, IFN-gamma, and IL-17 in protection against Streptococcus pneumoniae infection in response to alpha-galactosylceramide. J Infect Dis 206: 723–734.
152. Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, et al. (2003) CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 197: 1051–1057.
153. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, et al. (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 104: 3984–3989.
154. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, et al. (2008) NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A 105: 8339–8344.
155. Tonti E, Fedeli M, Napolitano A, Iannacone M, von Andrian UH, et al. (2012) Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol 188: 3217–3222.
156. King IL, Fortier A, Tighe M, Dibble J, Watts GF, et al. (2011) Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat Immunol 13: 44–50.
157. Chang PP, Barral P, Fitch J, Pratama A, Ma CS, et al. (2011) Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol 13: 35–43.
158. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK, (2005) Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J Immunol 174: 1787–1790.
159. Miyasaka T, Akahori Y, Toyama M, Miyamura N, Ishii K, et al. (2013) Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine. PLoS ONE 8: e78611.
160. Miyasaka T, Aoyagi T, Uchiyama B, Oishi K, Nakayama T, et al. (2012) A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings. Vaccine 30: 3304–3310.
161. Bai L, Deng S, Reboulet R, Mathew R, Teyton L, et al. (2013) Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A 110: 16097–16102.
162. Deng S, Bai L, Reboulet R, Matthew R, Engler DA, et al. (2014) A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses. Chem Sci 5: 1437–1441.